Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

481 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-01

Study Completion Date

2020-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

NCT03969212

Influenza

COMPLETED PHASE3

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

NCT02523287

Safety Markers of Adjuvanted Influenza Vaccine

COMPLETED PHASE4

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

NCT02071329

Influenza A

COMPLETED PHASE1/PHASE2

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

NCT05569239

Influenza

ACTIVE_NOT_RECRUITING PHASE2

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

NCT05027932

Influenza

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Households represent an important location for transmission of influenza. Rapid delivery of Xofluza may reduce household exposures to influenza among susceptible individuals.This study is a pilot study of a home-based approach to influenza infection control, utilizing self-test kits and rapid home delivery of an antiviral. Households with at least 3 individuals residing there at least 4 days a week, including at least 2 household members that are eligible to take antiviral, will be monitored throughout the influenza season for the onset of a cough or two or more acute respiratory infection symptoms. This study will be conducted in households in the Seattle, WA area for one influenza season, beginning November 1, 2019 and ending April 1, 2020. Household will self-monitor for onset of symptoms throughout the influenza season. When symptoms develop, the participant will self-test for influenza infection using a prepositioned home-testing kit. If negative, the ill participant will provide one self-collected nasal swab specimen. If positive, the ill participant will connect with a healthcare provider via the tele-health app on their smartphone to confirm the influenza diagnosis. Next, if eligible to receive Xofluza, the influenza-positive individual will receive a rapid home delivery of Xofluza within 2-6 hours of the positive test result. All influenza-positive participants will provide a self-collected nasal swab specimen at Study Day 0, Study Day 2-3, and Study Day 5-7. For all illness episodes, the ill individual will complete a questionnaire regarding symptom duration and severity, as well as behavioral changes due to illness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Respiratory Viral Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Drug Eligible

Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant

Group Type OTHER

Baloxavir Marboxil

Intervention Type DRUG

Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baloxavir Marboxil

Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xofluza

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Household Level:
* Group of at least 3 individuals of any ages defined as at least 3 persons residing at the same address for at least 4 days per calendar week
* Household group utilizes common household areas

Exclusion Criteria

* At least one member of the household has a smartphone
* Individual Level: Drug Eligible
* Resident of a household with 3 or more members (including eligible cases) for 4 or more days a calendar week
* Age 12 years or older weighing at least 40 kg (greater than 88 pounds)
* Willing and able to take study medication
* Willing to comply with all study procedures
* English-speaking
* Able to provide written, informed consent and/or assent (if applicable)
* Permanent mailing address that is available for study staff to mail necessary materials
* Individual Level: Drug Ineligible
* Resident of a household with 3 or more members (including eligible cases) for 4 or more days a calendar week
* Willing to comply with all study procedures
* English-speaking
* Able to provide written, informed consent and/or assent (if applicable)

* Household Level:
* Previous documentation of an influenza infection prior to or during the annual influenza season in any household member prior to enrollment
* Individual Level:
* Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration
* Individuals with hypersensitivity to baloxavir
* Individuals that already have a tele-health account
* Any individual that has one or more of the following conditions:
* Pregnant
* Currently lactating
* Immunosuppressed or immunocompromised (by disease or medication)
* Cancer
* Liver disease
* Kidney disease

Minimum Eligible Age

3 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes